Eli Lilly vs Telix Pharmaceuticals
Eli Lilly holds the stronger position because its moat is deeper and it faces heavier direct pressure from Novo Nordisk in a two-player race, while Telix faces competition on two fronts from Lantheus and Novartis, even though both companies carry concentration risk in one product line.
Eli Lilly
Eli Lilly is a pharma giant whose obesity drug tirzepatide now drives most of its revenue
Telix Pharmaceuticals
Telix makes PSMA-PET imaging drugs and radiopharmaceuticals for prostate cancer diagnosis and treatment
Dimension by dimension
| Dimension | Eli Lilly | Telix Pharmaceuticals |
|---|---|---|
| Staying power of the core product | Tirzepatide is driving nearly all of Lilly's growth, with revenue up over 50% in recent quarters, giving the product real staying power even as most of the company now rides on one drug. | Telix's PSMA-PET imaging and radiotherapeutics are growing fast, with Precision Medicine revenue up 30% year over year, but the company is still pushing into a radioligand therapy market Novartis already leads. |
| Exposure to AI | Lilly's obesity and diabetes drugs are also physical treatments that AI cannot replace or generate. | Telix's imaging agents and radiotherapeutics are physical drugs administered to patients, so AI is unlikely to absorb the product. |
| How easily a giant copies them | Lilly's tirzepatide is similarly protected and blocked from being copied outright, though Novo Nordisk is racing to match it with competing GLP-1 products. | Telix's approved radiopharmaceuticals are protected and blocked from easy copying, though it is entering a segment where Novartis is already entrenched. |
| Pressure from rivals | Lilly faces one dominant rival in Novo Nordisk, whose oral Wegovy pill has already launched in Europe and the UK ahead of Lilly's own oral GLP-1. | Telix faces competition on two fronts, squeezed by Lantheus in imaging and Novartis in radioligand therapy, both large competitors. |
| Financial footing | Lilly posted US$65.18 billion in FY2025 revenue, up 44.7% year over year, and continued at roughly 55% growth into Q1 2026, operating at a vastly larger scale. | Telix posted US$247 million in Q2 2026 revenue and guides to more than US$1 billion for the full year, a company still scaling up. |
| Overall standing | As of this assessment in July 2026, Lilly's scale and growth remain strong, though nearly two thirds of its revenue now depends on a single drug. | As of this assessment in July 2026, Telix's smaller revenue base and the two-front competitive pressure it faces while entering a new therapy category leave it on less certain footing. |
Questions people ask
- How dependent is Eli Lilly on one drug compared to Telix?
- Lilly's tirzepatide made up about 65% of its Q1 2026 revenue, showing heavy reliance on a single product. Telix's Precision Medicine segment was US$202 million of its US$247 million total Q2 2026 revenue, so both companies lean heavily on one part of their business.
- Which company has stronger revenue growth, Telix or Eli Lilly?
- Both are growing quickly. Telix's Precision Medicine revenue rose 30% year over year in Q2 2026, while Lilly's total revenue rose about 55% in Q1 2026, a faster pace at a much larger scale.
- Can Novartis or a large rival easily copy what Telix or Lilly do?
- Neither company is easy to copy outright, since both are rated as blocked on that measure. Telix's imaging agents and Lilly's tirzepatide are protected, though Novartis in radioligand therapy and Novo Nordisk in GLP-1 drugs are the closest competing threats to each.
Other comparisons with these companies